News

News Subscription

Jun 12. 2014
Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem
Read more
Download
Jun 02. 2014
Basilea's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study
Read more
Download
May 14. 2014
Basilea reports additional data on positive isavuconazole phase 3 SECURE study at ECCMID
Read more
Download
May 13. 2014
Basilea presents new data on its antibiotics pipeline at ECCMID
Read more
Download
Apr 10. 2014
Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
Read more
Download
Apr 07. 2014
Basilea's oncology drug candidate BAL101553 demonstrates broad antitumor activity in treatment-resistant breast cancer models as presented at AACR
Read more
Download
Feb 28. 2014
Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America
Read more
Download
Feb 27. 2014
Basilea reports that isavuconazole receives Qualified Infectious Disease Product designation from U.S. FDA for the treatment of invasive mucormycosis
Read more
Download
Feb 11. 2014
Basilea 2013 full-year results: strong operational and financial performance
Read more
Download
Dec 03. 2013
Basilea reports that isavuconazole receives Qualified Infectious Disease Product (QIDP) designation from U.S. FDA for the treatment of invasive aspergillosis
Read more
Download